Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fexagratinib - Abbisko Therapeutics

Next Previous
Drug Profile

Fexagratinib - Abbisko Therapeutics

Alternative Names: ABSK-091; AZD-4547

Latest Information Update: 16 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Developer Abbisko Therapeutics; AstraZeneca; Dust Diseases Authority; Institute of Respiratory Health; National Cancer Institute (USA); University of Glasgow; University of Leeds; University of Wisconsin-Madison
  • Class Antineoplastics; Benzamides; Phenyl ethers; Piperazines; Pyrazoles; Small molecules
  • Mechanism of Action Type 1 fibroblast growth factor receptor antagonists; Type 3 fibroblast growth factor receptor antagonists; Type-2 fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Gastric cancer; Lymphoma; Multiple myeloma; Solid tumours; Urogenital cancer
  • Preclinical Skin cancer
  • No development reported Liver cancer
  • Discontinued Bladder cancer; Breast cancer; Glioblastoma; Head and neck cancer; Lung cancer; Mesothelioma; Non-small cell lung cancer; Oesophageal cancer

Most Recent Events

  • 13 Feb 2025 Efficacy and adverse events data from a phase II trial in Urothelial carcinoma presented at the 2025 Genitourinary Cancers Symposium (ASCO-GeCS-2025)
  • 13 Feb 2025 Efficacy, and adverse events data from phase I/II trial in Urogenital cancer presented at the Genitourinary Cancers Symposium (ASCO-GU-2025)
  • 13 Sep 2024 Pharmacodynamics data from the preclinical studies in Solid tumours presented at the 49th European Society for Medical Oncology Congress (ESMO-2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top